Dr. Errol Gordon, MD
Claim this profileSt. John Medical Center
Studies Stroke
Studies Hemorrhagic Stroke
3 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Errol Gordon, MD is currently running
Tissue Kallikrein
for Ischemic Stroke
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at up to approximately 100 sites.
Recruiting0 awards Phase 2 & 37 criteria
rFVIIa
for Hemorrhagic Stroke
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.
Recruiting1 award Phase 34 criteria
More about Errol Gordon, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Errol Gordon, MD has experience with
- Placebo
- Recombinant Activated Factor VII (rFVIIa)
- Recombinant Human Tissue Kallikrein
- Argatroban
- Eptifibatide
Breakdown of trials Errol Gordon, MD has run
Stroke
Hemorrhagic Stroke
Bleeding
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Errol Gordon, MD specialize in?
Errol Gordon, MD focuses on Stroke and Hemorrhagic Stroke. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Errol Gordon, MD currently recruiting for clinical trials?
Yes, Errol Gordon, MD is currently recruiting for 2 clinical trials in Tulsa Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Errol Gordon, MD has studied deeply?
Yes, Errol Gordon, MD has studied treatments such as Placebo, Recombinant Activated Factor VII (rFVIIa), Recombinant human tissue kallikrein.
What is the best way to schedule an appointment with Errol Gordon, MD?
Apply for one of the trials that Errol Gordon, MD is conducting.
What is the office address of Errol Gordon, MD?
The office of Errol Gordon, MD is located at: St. John Medical Center, Tulsa, Oklahoma 74104 United States. This is the address for their practice at the St. John Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.